17例经脑活检确诊的原发性中枢神经系统血管炎患者的各临床亚型特点分析OA北大核心CSTPCDMEDLINE
Clinical Features of 17 Patients With Primary Angiitis of the Central Nervous System Confirmed by Brain Biopsy
目的 分析17例原发性中枢神经系统血管炎(PACNS)各临床亚型特点,以促进对PACNS的早期诊断、治疗,减少复发率及死亡率,改善预后.方法 收集2009年1月至2023年6月收治的脑活检确诊的PACNS患者,分析其临床表现,实验室、影像学、电生理、病理等检查结果,以及治疗和预后情况.结果 17例脑活检病理检查确诊的PACNS患者中,儿童1例、成人16例.瘤样PACNS 10例,脊髓受累PACNS 2例,血管造影阳性PACNS 3例,快速进展性PACNS 2例,出血性PACNS 1例,淀粉样蛋白β相关性PACNS 1例.11例合并继发性癫痫(64.7%),所有患者头部MRI异常,94.1%MRI增强有病灶周边或软脑膜不均匀强化,3例MRI血管成像显示大血管病变,2例脊髓受累.病理分型:淋巴细胞性血管炎7例(43.7%),坏死性血管炎5例(31.2%).17例中11例应用糖皮质激素+环磷酰胺治疗,6例维持治疗3个月后复查头部MRI有病灶部分消失并临床症状明显改善;2例快速进展;1例死亡;3例1年内复发;3例对激素治疗不敏感,遗留残疾;2例复发后使用利妥昔单抗治疗,随访6个月~1年,临床稳定.结论 瘤样PACNS更易出现癫痫,男性多见,最常见病理类型为坏死性血管炎,通常对激素治疗效果好,预后相对较好,因此,对于年轻的合并癫痫颅内肿瘤样病灶的患者,应注意排查PACNS的可能.脊髓受累PACNS病变多位于胸髓和颈髓,多提示预后不佳,肌电图多显示为前角或根受累的失神经电位,对于鉴别诊断有一定价值,建议怀疑脊髓受累患者,完善肌电图检查.快速进展性PACNS多合并幕下病变,如脑桥、延髓等,死亡率高.出血性PACNS少见,年轻患者且颅内出现多发出血病灶并强化者应注意鉴别.对于复发进展的患者,利妥昔单抗是值得推荐的治疗选择.
Objective To analyze the clinical features of 17 patients with primary angiitis of the central nervous system(PACNS)and thus facilitate the early diagnosis and treatment,reduce the recurrence and mortal-ity,and improve the prognoses of this disease.Methods We collected the data of patients with PACNS diag-nosed by brain biopsy from January 2009 to June 2023 and analyzed their clinical presentations,laboratory and imaging manifestations,electrophysiological and pathological changes,and treatment regimens and prognosis.Results The 17 patients diagnosed with PACNS via brain biopsy included one child and 16 adults.The subtyp-ing results showed that 10,2,3,2,1,and 1 patients had tumorous,spinal cord-involved,angiography-posi-tive,rapidly progressive,hemorrhagic,and amyloid β-related PACNS,respectively.Eleven(64.7%)of the patients were complicated with secondary epilepsy.All the patients exhibited abnormal manifestations in head MRI,with 94.1%showing lesions with uneven enhancement around the lesions or in the leptomeninges.Mag-netic resonance angiography revealed large vessel abnormalities in 3 patients,and spinal cord involvement was observed in 2 patients.Histopathological typing revealed 7(43.7%)patients with lymphocytic vasculitis and 5(31.2%)patients with necrotizing vasculitis.Eleven patients were treated with glucocorticoids and cyclophospha-mide,which resulted in partial lesion disappearance and symptom amelioration in 6 patients upon reevaluation with head MRI after 3 months of maintenance therapy.Two,1,and 3 patients experienced rapid disease progres-sion,death,and recurrence within 1 year,respectively.Three patients showed insensitivity to hormonotherapy and residual disabilities.Two patients received rituximab after relapse and remained clinically stable during a fol-low-up period of 0.5-1 year.Conclusions Tumorous PACNS was more prone to epilepsy,mainly occurring in males.The most common histopathological type was necrotizing vasculitis,which responded to hormonotherapy and had favorable outcomes.Therefore,for the young patients with epilepsy and intracranial tumorous lesions,the possibility of PACNS should be considered.Spinal cord involvement in PACNS was often located in the thorac-ic and cervical cords,suggesting a poorer prognosis.Electromyography commonly revealed neural conduction ab-normalities in the anterior horn or roots,providing clues for differential diagnosis.For suspected spinal cord in-volvement,comprehensive electromyography is recommended.Rapidly progressive PACNS often presented infrat-entorial lesions,such as lesions in the pons and medulla,with a higher mortality rate.Hemorrhagic PACNS was rare,and a multifocal hemorrhagic lesion with enhancement in the intracranial region,particularly in young pa-tients,should raise suspicion.For the patients with recurrent or progressive disease,rituximab is a recommended therapeutic option.
张莉;孙慧;张世敏;高赛;武雷;黄德晖
中国人民解放军总医院第一医学中心神经内科医学部,北京 100853||南阳市第一人民医院神经内科,河南南阳 473000中国人民解放军总医院第一医学中心神经内科医学部,北京 100853
临床医学
原发性中枢神经系统血管炎临床亚型肌电图MRI利妥昔单抗
primary angiitis of the central nervous systemclinical subtypeelectromyographyMRIrituximab
《中国医学科学院学报》 2024 (004)
546-553 / 8
中国研究型医院学会科研课题(Y2023FH-5JK09)
评论